Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM
Authors' conclusion
Co-agonism of GPR40 and GPR119 with K-757 and K-833 elicits rapid, robust and glucose-dependent glucose lowering and modest weight loss in patients with T2DM on stable metformin.
Study context
- Population
- Overweight-obese adults with T2DM maintained on metforminStudy 1: 12 placebo, 13 combination
- Comparison
- K-757 + K-833 vs placebo
Methodological detailstwo studies, double-blind, placebo-controlled, phase 1
- Two studies
- Double-blind
- Placebo-controlled
- Phase 1
Primary result
As reported in the abstract
Placebo-corrected LS mean reductions from baseline (Study 1) · 28 days
24 h-WMG reduction, K-757 + K-833 vs placebo
77.3 mg/dL
FPG reduction, K-757 + K-833 vs placebo
64.0 mg/dL
A1C reduction, K-757 + K-833 vs placebo
0.55%
Body weight reduction, K-757 + K-833 vs placebo
1.61%
Further findings
Placebo-corrected LS mean reductions from baseline (Study 2) · 42 days
- FPG reduction, K-757 + K-833 vs placebo
- 25.2 mg/dL
- A1C reduction, K-757 + K-833 vs placebo
- 0.26%
- Body weight reduction, K-757 + K-833 vs placebo
- 4.95%
- Study 2: 24 enrolled
Original publication
Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM. Diabetes Obes Metab. Published 6 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →